Pacific Biosciences of California, Inc.
PACB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $502,313 | $2,488,100 | $1,836,819 | $4,166,093 |
| - Cash | $55,370 | $179,911 | $325,089 | $460,725 |
| + Debt | $672,434 | $933,930 | $948,481 | $955,355 |
| Enterprise Value | $1,119,377 | $3,242,119 | $2,460,211 | $4,660,723 |
| Revenue | $154,014 | $200,521 | $128,304 | $130,513 |
| % Growth | -23.2% | 56.3% | -1.7% | – |
| Gross Profit | $37,282 | $52,780 | $49,035 | $58,860 |
| % Margin | 24.2% | 26.3% | 38.2% | 45.1% |
| EBITDA | -$242,772 | -$271,125 | -$282,240 | -$250,757 |
| % Margin | -157.6% | -135.2% | -220% | -192.1% |
| Net Income | -$309,851 | -$306,735 | -$314,248 | -$181,223 |
| % Margin | -201.2% | -153% | -244.9% | -138.9% |
| EPS Diluted | -1.07 | -1.21 | -1.4 | -0.89 |
| % Growth | 11.6% | 13.6% | -57.3% | – |
| Operating Cash Flow | -$206,058 | -$266,548 | -$263,211 | -$111,180 |
| Capital Expenditures | -$6,188 | -$8,843 | -$16,929 | -$5,931 |
| Free Cash Flow | -$212,246 | -$275,391 | -$280,140 | -$117,111 |